The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.
A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk / Travis R.C.; Appleby P.N.; Martin R.M.; Holly J.M.P.; Albanes D.; Black A.; Bueno-De-Mesquita H.B.; Chan J.M.; Chen C.; Chirlaque M.-D.; Cook M.B.; Deschasaux M.; Donovan J.L.; Ferrucci L.; Galan P.; Giles G.G.; Giovannucci E.L.; Gunter M.J.; Habel L.A.; Hamdy F.C.; Helzlsouer K.J.; Hercberg S.; Hoover R.N.; Janssen J.A.M.J.L.; Kaaks R.; Kubo T.; Le Marchand L.; Metter E.J.; Mikami K.; Morris J.K.; Neal D.E.; Neuhouser M.L.; Ozasa K.; Palli D.; Platz E.A.; Pollak M.N.; Price A.J.; Roobol M.J.; Schaefer C.; Schenk J.M.; Severi G.; Stampfer M.J.; Stattin P.; Tamakoshi A.; Tangen C.M.; Touvier M.; Wald N.J.; Weiss N.S.; Ziegler R.G.; Key T.J.; Allen N.E.. - In: CANCER RESEARCH. - ISSN 0008-5472. - STAMPA. - 76:(2016), pp. 2288-2300. [10.1158/0008-5472.CAN-15-1551]
A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk
Severi G.;
2016
Abstract
The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
